Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Müller

Showing results (71-80 of 1,471) with videos related to

Pageof 148
Sort By:
MMW Fortschritte Der Medizin|January 17, 2018
Thomas Müller
MMW Fortschritte Der Medizin|February 9, 2018
Thomas Müller
Expert Opinion on Investigational Drugs|July 22, 2010
New small molecules for the treatment of Parkinson's diseaseThomas Müller
Expert Opinion on Drug Metabolism & Toxicology|May 7, 2013
Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerationsThomas Müller
Expert Review of Neurotherapeutics|September 24, 2013
Current status of safinamide for the drug portfolio of Parkinson's disease therapyThomas Müller
Expert Review of Neurotherapeutics|June 7, 2013
Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson's diseaseThomas Müller
MMW Fortschritte Der Medizin|September 9, 2014
[Suicide risk in minors. A new explosive in the antidepressant debate]Thomas Müller
Neurology International|March 27, 2026
No New Relevant Treatment Options for L-DOPA-Induced Dyskinesia from a Clinician's Point of ViewThomas Müller
MMW Fortschritte Der Medizin|November 16, 2016
Thomas Müller
Expert Opinion on Investigational Drugs|December 9, 2016
Investigational agents for the management of Huntington's diseaseThomas Müller
Pageof 148

Showing results (71-80 of 1,471) with videos related to

Sort By:
Pageof 148
MMW Fortschritte Der Medizin|January 17, 2018
Thomas Müller
MMW Fortschritte Der Medizin|February 9, 2018
Thomas Müller
Expert Opinion on Investigational Drugs|July 22, 2010
New small molecules for the treatment of Parkinson's diseaseThomas Müller
Expert Opinion on Drug Metabolism & Toxicology|May 7, 2013
Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerationsThomas Müller
Expert Review of Neurotherapeutics|September 24, 2013
Current status of safinamide for the drug portfolio of Parkinson's disease therapyThomas Müller
Expert Review of Neurotherapeutics|June 7, 2013
Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson's diseaseThomas Müller
MMW Fortschritte Der Medizin|September 9, 2014
[Suicide risk in minors. A new explosive in the antidepressant debate]Thomas Müller
Neurology International|March 27, 2026
No New Relevant Treatment Options for L-DOPA-Induced Dyskinesia from a Clinician's Point of ViewThomas Müller
MMW Fortschritte Der Medizin|November 16, 2016
Thomas Müller
Expert Opinion on Investigational Drugs|December 9, 2016
Investigational agents for the management of Huntington's diseaseThomas Müller
Pageof 148